Open Access. Powered by Scholars. Published by Universities.®
- Publication
Articles 1 - 3 of 3
Full-Text Articles in Entire DC Network
Evaluating The Therapeutic Potential Of Crocin Against Diethylnitrosamine Induced Experimental Hepatocellular Carcinoma In Rats, Basma Ali Mustafa Awad
Evaluating The Therapeutic Potential Of Crocin Against Diethylnitrosamine Induced Experimental Hepatocellular Carcinoma In Rats, Basma Ali Mustafa Awad
Theses
Hepatocellular carcinoma (HCC) is the fifth most common type of cancer and the third cause of cancer-related death worldwide. Liver cancer is the result of repeated injuries to the liver triggered by different causes. Currently, sorafenib is the only drug U.S. Food and Drug Administration approved targeted therapy. Sorafenib, an oral multikinase inhibitor, which inhibits the proliferation of tumor cells and blocks angiogenesis. Sorafenib has been shown to treat early and mild HCC lesions and it helped increase the survival rates at one year, but for only 44% of patients. Chemotherapies are an important line of defense when it comes …
In Vivo Assessment Of Safranal’S Novel Therapeutic Effects On Chemically Induced Hepatic Neoplasia, Ameera Ali M. Almansoori
In Vivo Assessment Of Safranal’S Novel Therapeutic Effects On Chemically Induced Hepatic Neoplasia, Ameera Ali M. Almansoori
Biology Theses
Chronic liver insult leads to fibrosis, which often ends up causing cirrhosis and most of the time that progresses into hepatic neoplasms (early Hepatocellular carcinoma; HCC). HCC is the fifth most common cancer, and the third cause of cancerrelated deaths. Chemotherapy is the most common treatment of cancer patients. HCC is however, chemo-resistant, and the side-effects of chemotherapy are typically exhausting to the patient. Sorafenib is the only anti-HCC drug approved by the U.S Food and Drug Administration. It is a multikinase inhibitor that blocks tumor cells proliferation and angiogenesis. Although sorafenib is successful treating early and mid HCC lesions, …
Transcriptomic Analysis On Hepatocellular Carcinoma Model In Response To Safranal Treatment, Badriya Mahmood Ahmed Baig
Transcriptomic Analysis On Hepatocellular Carcinoma Model In Response To Safranal Treatment, Badriya Mahmood Ahmed Baig
Biology Theses
Unsolved riddle of cancer remains a major global health concern particularly in hepatocellular carcinoma (HCC) which is among the leading causes of cancer related death worldwide. Saffron (Crocus sativus L.) and its bioactive phytochemicals possess promising anti-cancer activities. One of these phytochemicals, safranal, has demonstrated potent anti-cancer activities against different types of cancers. Yet, its association with liver cancer remains under documented. This study investigated HCC response to safranal’s treatment via transcriptomic approach. Safranal was found to be involved in mitochondrial dysfunction, induced oxidative stress and increased reactive oxygen species (ROS) production leading to cell death. Interestingly, safranal has …